The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Cilta-cel in lenalidomide-refractory MM patients: updates from cohort A of the CARTITUDE-2 trial
In this video, Yael Cohen, MD, Tel-Aviv Sourasky Medical center, Tel-Aviv, Israel, shares some updated results from a 17-month follow-up of the CARTITUDE-2 study (NCT04133636), evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory myeloma patients. Dr Cohen first discusses the patient cohort being evaluated, and then highlights the overall response rates (ORR) and measurable residual disease (MRD) negative responses observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
